Destruction of tumor vasculature by vascular disrupting agents in overcoming the limitation of EPR effect

The Use of Alternative Strategies for Enhanced Nanoparticle Delivery to Solid Tumors

(2021) Mukaddes Izci et al.   CHEMICAL REVIEWS

Platelet-Membrane-Coated Nanoparticles Enable Vascular Disrupting Agent Combining Anti-Angiogenic Drug for Improved Tumor Vessel Impairment

(2021) Bozhao Li et al.   NANO LETTERS

Hypoxia-Activated Prodrug Enabling Synchronous Chemotherapy and HIF-1α Downregulation for Tumor Treatment

(2021) Xiangjie Luo et al.   BIOCONJUGATE CHEMISTRY

Prodrug-Based Versatile Nanomedicine with Simultaneous Physical and Physiological Tumor Penetration for Enhanced Cancer Chemo-Immunotherapy

(2021) Zhaopei Guo et al.   NANO LETTERS

Co-administration of combretastatin A4 nanoparticles and anti-PD-L1 for synergistic therapy of hepatocellular carcinoma

(2021) Bonan Zhao et al.   JOURNAL OF NANOBIOTECHNOLOGY

Direct and Indirect Modulation of T Cells by VEGF-A Counteracted by Anti-Angiogenic Treatment

(2021) Morgane Bourhis et al.   Frontiers in Immunology

Selective Thrombosis of Tumor for Enhanced Hypoxia‐Activated Prodrug Therapy

(2021) Zhaoyu Ma et al.   ADVANCED MATERIALS

Engineering Nanorobots for Tumor‐Targeting Drug Delivery: From Dynamic Control to Stimuli‐Responsive Strategy

(2021) Lujia Huang et al.   CHEMBIOCHEM

Nanoparticles Composed of PEGylated Alternating Copolymer‐Combretastatin A4 Conjugate for Cancer Therapy

(2021) Yu Zhang et al.   MACROMOLECULAR BIOSCIENCE

Flavonoid-Inspired Vascular Disrupting Agents: Exploring Flavone-8-Acetic Acid and Derivatives in the New Century

(2021) Silvia Gobbi et al.   MOLECULES

Role of VEGFs/VEGFR-1 Signaling and Its Inhibition in Modulating Tumor Invasion: Experimental Evidence in Different Metastatic Cancer Models

(2020) Claudia Ceci et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Theranostic MRI liposomes for magnetic targeting and ultrasound triggered release of the antivascular CA4P

(2020) Caroline J. Thébault et al.   JOURNAL OF CONTROLLED RELEASE

Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges

(2020) John D. Martin et al.   Nature Reviews Clinical Oncology

Chemotaxis-driven delivery of nano-pathogenoids for complete eradication of tumors post-phototherapy

(2020) Min Li et al.   Nature Communications

Enzyme-Triggered Transcytosis of Dendrimer–Drug Conjugate for Deep Penetration into Pancreatic Tumors

(2020) Guowei Wang et al.   ACS Nano

Antiangiogenic Agents: A Review on Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) Inhibitors

(2020) Kang Cheng et al.   CURRENT MEDICINAL CHEMISTRY

Microtubule-targeting agents and their impact on cancer treatment

(2020) Vladimír Čermák et al.   EUROPEAN JOURNAL OF CELL BIOLOGY

Hypoxia-sensitive supramolecular nanogels for the cytosolic delivery of ribonuclease A as a breast cancer therapeutic

(2020) Xinghui Si et al.   JOURNAL OF CONTROLLED RELEASE

Colchicine Alkaloids, and Synthetic Analogues: Current Progress and Perspectives

(2020) Iuliia Alexandrovna Gracheva et al.   JOURNAL OF MEDICINAL CHEMISTRY

Bioreductively Activatable Prodrug Conjugates of Combretastatin A-1 and Combretastatin A-4 as Anticancer Agents Targeted toward Tumor-Associated Hypoxia

(2020) Blake A. Winn et al.   JOURNAL OF NATURAL PRODUCTS

Exploiting the dynamics of the EPR effect and strategies to improve the therapeutic effects of nanomedicines by using EPR effect enhancers

(2020) Jun Fang et al.   ADVANCED DRUG DELIVERY REVIEWS

Cancer stromal targeting therapy to overcome the pitfall of EPR effect

(2020) Yasuhiro Matsumura   ADVANCED DRUG DELIVERY REVIEWS

Spatiotemporally Targeted Nanomedicine Overcomes Hypoxia-Induced Drug Resistance of Tumor Cells after Disrupting Neovasculature

(2020) Jinjin Chen et al.   NANO LETTERS

Vascular disrupting agent induced aggregation of gold nanoparticles for photothermally enhanced tumor vascular disruption

(2020) Sheng Hong et al.   Science Advances

Molecularly imprinted polymer‐based smart prodrug delivery system for specific targeting, prolonged retention and tumor microenvironment‐triggered release

(2020) Zikuan Gu et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity

(2020) Won Suk Lee et al.   EXPERIMENTAL AND MOLECULAR MEDICINE

Poly(L‐Glutamic Acid)‐Drug Conjugates for Chemo‐ and Photodynamic Combination Therapy

(2020) Haiyang Yu et al.   MACROMOLECULAR BIOSCIENCE

Active Transportation of Liposome Enhances Tumor Accumulation, Penetration, and Therapeutic Efficacy

(2020) Guowei Wang et al.   Small

Recent Advances in Nanocarrier-Assisted Therapeutics Delivery Systems

(2020) Shi Su et al.   Pharmaceutics

Self‐Amplifying Nanotherapeutic Drugs Homing to Tumors in a Manner of Chain Reaction

(2020) Yue Wang et al.   ADVANCED MATERIALS

Vascular disrupting agents in cancer therapy

(2020) Ryszard Smolarczyk et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Vessel co-option in cancer

(2019) Elizabeth A. Kuczynski et al.   Nature Reviews Clinical Oncology

Selectively Potentiating Hypoxia Levels by Combretastatin A4 Nanomedicine: Toward Highly Enhanced Hypoxia-Activated Prodrug Tirapazamine Therapy for Metastatic Tumors

(2019) Shengcai Yang et al.   ADVANCED MATERIALS

Co-administration of combretastatin A4 nanoparticles and sorafenib for systemic therapy of hepatocellular carcinoma

(2019) Yalin Wang et al.   Acta Biomaterialia

PI3Kgamma Inhibitor Attenuates Immunosuppressive Effect of Poly( l ‐Glutamic Acid)‐Combretastatin A4 Conjugate in Metastatic Breast Cancer

(2019) Hanjiao Qin et al.   Advanced Science

Small-Molecule CSF1R Inhibitors as Anticancer Agents

(2019) Xiaoyun Lu et al.   CURRENT MEDICINAL CHEMISTRY

CD30 aptamer-functionalized PEG-PLGA nanoparticles for the superior delivery of doxorubicin to anaplastic large cell lymphoma cells

(2019) Xiao Luo et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

Glucose and pH Dual‐Responsive Nanogels for Efficient Protein Delivery

(2019) Xinghui Si et al.   MACROMOLECULAR BIOSCIENCE

Enzyme-activatable polymer–drug conjugate augments tumour penetration and treatment efficacy

(2019) Quan Zhou et al.   Nature Nanotechnology

Vascular Disrupting Agents in cancer treatment: Cardiovascular toxicity and implications for co-administration with other cancer chemotherapeutics

(2019) Jason H. Gill et al.   PHARMACOLOGY & THERAPEUTICS

Rapamycin suppresses angiogenesis and lymphangiogenesis in melanoma by downregulating VEGF-A/VEGFR-2 and VEGF-C/VEGFR-3 expression

(2019) Min Wang et al.   OncoTargets and Therapy

Smart Nanotherapeutic Targeting of Tumor Vasculature

(2019) Zifu Li et al.   ACCOUNTS OF CHEMICAL RESEARCH

Survey of Clinical Translation of Cancer Nanomedicines—Lessons Learned from Successes and Failures

(2019) Hongliang He et al.   ACCOUNTS OF CHEMICAL RESEARCH

Combretastatin A4 Nanodrug‐Induced MMP9 Amplification Boosts Tumor‐Selective Release of Doxorubicin Prodrug

(2019) Jian Jiang et al.   ADVANCED MATERIALS

Enhancing intratumoral biodistribution and antitumor activity of nab-paclitaxel through combination with a vascular disrupting agent, combretastatin A-4-phosphate

(2019) Meng Gao et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Longitudinal photoacoustic imaging of the pharmacodynamic effect of vascular targeted therapy on tumors

(2019) Sean Peter Johnson et al.   CLINICAL CANCER RESEARCH

GEF-H1 Signaling upon Microtubule Destabilization Is Required for Dendritic Cell Activation and Specific Anti-tumor Responses

(2019) Abhishek S. Kashyap et al.   Cell Reports

pH-Responsive and Gemcitabine-Containing DNA Nanogel To Facilitate the Chemodrug Delivery

(2019) Gaifang Pan et al.   ACS Applied Materials & Interfaces

Platelet-Mimicking Biotaxis Targeting Vasculature-Disrupted Tumors for Cascade Amplification of Hypoxia-Sensitive Therapy

(2019) Mingkang Zhang et al.   ACS Nano

The Vascular Disrupting Agent CA4P Improves the Antitumor Efficacy of CAR-T Cells in Preclinical Models of Solid Human Tumors

(2019) Changwen Deng et al.   MOLECULAR THERAPY

Combretastatin A4 Nanoparticles Combined with Hypoxia-Sensitive Imiquimod: A New Paradigm for the Modulation of Host Immunological Responses during Cancer Treatment

(2019) Na Shen et al.   NANO LETTERS

A novel GSH responsive poly(alpha-lipoic acid) nanocarrier bonding with the honokiol-DMXAA conjugate for combination therapy

(2019) Zhilin Liu et al.   Science China-Materials

Plinabulin ameliorates neutropenia induced by multiple chemotherapies through a mechanism distinct from G-CSF therapies

(2019) James R. Tonra et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Hypoxia-induced activity loss of a photo-responsive microtubule inhibitor azobenzene combretastatin A4

(2019) Yang An et al.   Frontiers of Chemical Science and Engineering

An overview on Vadimezan (DMXAA): The vascular disrupting agent

(2018) Amir Daei Farshchi Adli et al.   Chemical Biology & Drug Design

Biomarker Displacement Activation: A General Host–Guest Strategy for Targeted Phototheranostics in Vivo

(2018) Jie Gao et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Nanoparticle anchoring targets immune agonists to tumors enabling anti-cancer immunity without systemic toxicity

(2018) Yuan Zhang et al.   Nature Communications

Enzyme/pH-sensitive dendritic polymer-DOX conjugate for cancer treatment

(2018) Kai Chen et al.   Science China-Materials

Histopathological and functional changes in a single-dose model of combretastatin A4 disodium phosphate-induced myocardial damage in rats

(2018) Ryota TOCHINAI et al.   Journal of Toxicologic Pathology

Tumor-Acidity-Cleavable Maleic Acid Amide (TACMAA): A Powerful Tool for Designing Smart Nanoparticles To Overcome Delivery Barriers in Cancer Nanomedicine

(2018) Jin-Zhi Du et al.   ACCOUNTS OF CHEMICAL RESEARCH

Evaluation of Sydnone-Based Analogues of Combretastatin A-4 Phosphate (CA4P) as Vascular Disrupting Agents for Use in Cancer Therapy

(2018) Andrew W. Brown et al.   ChemMedChem

Interactions of long-chain homologues of colchicine with tubulin

(2017) Ana Marzo-Mas et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Characterisation of aggregates of cyclodextrin-drug complexes using Taylor Dispersion Analysis

(2017) Hadar Zaman et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

Rationalized Computer-Aided Design of Matrix-Metalloprotease-Selective Prodrugs

(2017) Mohit Jain et al.   JOURNAL OF MEDICINAL CHEMISTRY

Hostile takeover: how tumours hijack pre-existing vascular environments to thrive

(2017) Frank Winkler   JOURNAL OF PATHOLOGY

Parameters Affecting the Enhanced Permeability and Retention Effect: The Need for Patient Selection

(2017) Az Alddien Natfji et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Polymer Prodrug-Based Nanoreactors Activated by Tumor Acidity for Orchestrated Oxidation/Chemotherapy

(2017) Junjie Li et al.   NANO LETTERS

Baicalein inhibits tumor progression by inhibiting tumor cell growth and tumor angiogenesis

(2017) Yang-Gyu Park et al.   ONCOLOGY REPORTS

Inhibiting Solid Tumor Growth In Vivo by Non-Tumor-Penetrating Nanomedicine

(2017) Shixian Lv et al.   Small

Recent advances in combretastatin based derivatives and prodrugs as antimitotic agents

(2017) Zaki S. Seddigi et al.   MedChemComm

Enhancing Nanoparticle Accumulation and Retention in Desmoplastic Tumors via Vascular Disruption for Internal Radiation Therapy

(2017) Andrew B. Satterlee et al.   Theranostics

The STING agonist DMXAA triggers a cooperation between T lymphocytes and myeloid cells that leads to tumor regression

(2017) Julia M. Weiss et al.   OncoImmunology

Rethinking cancer nanotheranostics

(2017) Hongmin Chen et al.   Nature Reviews Materials

Anti-angiogenic agents for the treatment of solid tumors: Potential pathways, therapy and current strategies – A review

(2017) Ahmed M. Al-Abd et al.   Journal of Advanced Research

Studying the influence of angiogenesis in in vitro cancer model systems

(2016) Laila C. Roudsari et al.   ADVANCED DRUG DELIVERY REVIEWS

Sonoporation enhances liposome accumulation and penetration in tumors with low EPR

(2016) Benjamin Theek et al.   JOURNAL OF CONTROLLED RELEASE

Blocking Blood Flow to Solid Tumors by Destabilizing Tubulin: An Approach to Targeting Tumor Growth

(2016) María-Jesús Pérez-Pérez et al.   JOURNAL OF MEDICINAL CHEMISTRY

Novel Natural Product- and Privileged Scaffold-Based Tubulin Inhibitors Targeting the Colchicine Binding Site

(2016) Mengqi Dong et al.   MOLECULES

Therapeutic application of anti-angiogenic nanomaterials in cancers

(2016) Sudip Mukherjee et al.   Nanoscale

Combretastatins: In vitro structure-activity relationship, mode of action and current clinical status

(2016) Karol Jaroch et al.   Pharmacological Reports

Solid Tumor Therapy Using a Cannon and Pawn Combination Strategy

(2016) Wantong Song et al.   Theranostics

Regulation of myeloid cells by activated T cells determines the efficacy of PD-1 blockade

(2016) Nina Eissler et al.   OncoImmunology

Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity

(2015) Hiroshi Maeda   ADVANCED DRUG DELIVERY REVIEWS

Exploring the size adaptability of the B ring binding zone of the colchicine site of tubulin with para-nitrogen substituted isocombretastatins

(2015) Carmen Jiménez et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions

(2014) Naveen S. Vasudev et al.   ANGIOGENESIS

Recent advances in vascular disrupting agents in cancer therapy

(2014) Elena Porcù et al.   Future Medicinal Chemistry

How Taxol/paclitaxel kills cancer cells

(2014) Beth A. Weaver   MOLECULAR BIOLOGY OF THE CELL

Tumor-Targeted Prodrug ICT2588 Demonstrates Therapeutic Activity against Solid Tumors and Reduced Potential for Cardiovascular Toxicity

(2014) Jason H. Gill et al.   MOLECULAR PHARMACEUTICS

CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8+T cells

(2014) Debbie C Strachan et al.   OncoImmunology

Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology

(2013) Nicolas Bertrand et al.   ADVANCED DRUG DELIVERY REVIEWS

Dual and multi-stimuli responsive polymeric nanoparticles for programmed site-specific drug delivery

(2013) Ru Cheng et al.   BIOMATERIALS

Structure-Function Analysis of STING Activation by c[G(2′,5′)pA(3′,5′)p] and Targeting by Antiviral DMXAA

(2013) Pu Gao et al.   CELL

Phase I Safety, Pharmacokinetic and Pharmacodynamic Evaluation of the Vascular Disrupting Agent Ombrabulin (AVE8062) in Patients with Advanced Solid Tumors

(2013) C. Sessa et al.   CLINICAL CANCER RESEARCH

Vascular priming enhances chemotherapeutic efficacy against head and neck cancer

(2013) Margaret Folaron et al.   ORAL ONCOLOGY

Molecular Mechanism of Action of Microtubule-Stabilizing Anticancer Agents

(2013) A. E. Prota et al.   SCIENCE

Development of Novel Tumor-Targeted Theranostic Nanoparticles Activated by Membrane-Type Matrix Metalloproteinases for Combined Cancer Magnetic Resonance Imaging and Therapy

(2013) Celina Ansari et al.   Small

VEGF-A recruits a proangiogenic MMP-9-delivering neutrophil subset that induces angiogenesis in transplanted hypoxic tissue

(2012) G. Christoffersson et al.   BLOOD

Interstitial Fluid and Lymph Formation and Transport: Physiological Regulation and Roles in Inflammation and Cancer

(2012) Helge Wiig et al.   PHYSIOLOGICAL REVIEWS

Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile

(2012) J. Hrkach et al.   Science Translational Medicine

2-Methoxycinnamaldehyde inhibits tumor angiogenesis by suppressing Tie2 activation

(2011) Daishi Yamakawa et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

A novel vascular disrupting agent plinabulin triggers JNK-mediated apoptosis and inhibits angiogenesis in multiple myeloma cells

(2011) A. V. Singh et al.   BLOOD

Water-Soluble Prodrug of Antimicrotubule Agent Plinabulin: Effective Strategy with Click Chemistry

(2011) Fumika Yakushiji et al.   CHEMISTRY-A EUROPEAN JOURNAL

The Tubulin Colchicine Domain: a Molecular Modeling Perspective

(2011) Alberto Massarotti et al.   ChemMedChem

A polymeric colchicinoid prodrug with reduced toxicity and improved efficacy for vascular disruption in cancer therapy

(2011) Bart J. Crielaard et al.   International Journal of Nanomedicine

Vascular effects of plinabulin (NPI-2358) and the influence on tumour response when given alone or combined with radiation

(2011) Lotte B. Bertelsen et al.   INTERNATIONAL JOURNAL OF RADIATION BIOLOGY

TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice

(2011) Abigail F. Welford et al.   JOURNAL OF CLINICAL INVESTIGATION

Tailor-Made Dual pH-Sensitive Polymer–Doxorubicin Nanoparticles for Efficient Anticancer Drug Delivery

(2011) Jin-Zhi Du et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Molecular and Cellular Pharmacology of the Hypoxia-Activated Prodrug TH-302

(2011) F. Meng et al.   MOLECULAR CANCER THERAPEUTICS

Molecular mechanisms and clinical applications of angiogenesis

(2011) Peter Carmeliet et al.   NATURE

Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size

(2011) H. Cabral et al.   Nature Nanotechnology

Cardiovascular Toxicity Profiles of Vascular-Disrupting Agents

(2011) I. M. Subbiah et al.   ONCOLOGIST

The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect

(2010) Jun Fang et al.   ADVANCED DRUG DELIVERY REVIEWS

Tubulin photoaffinity labeling study with a plinabulin chemical probe possessing a biotin tag at the oxazole

(2010) Yuri Yamazaki et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Development of a Novel Tumor-Targeted Vascular Disrupting Agent Activated by Membrane-Type Matrix Metalloproteinases

(2010) J. M. Atkinson et al.   CANCER RESEARCH

Matrix Metalloproteinase-14 (MT1-MMP)-Mediated Endoglin Shedding Inhibits Tumor Angiogenesis

(2010) L. J. A. C. Hawinkels et al.   CANCER RESEARCH

Phase 1 First-in-Human Trial of the Vascular Disrupting Agent Plinabulin(NPI-2358) in Patients with Solid Tumors or Lymphomas

(2010) M. M. Mita et al.   CLINICAL CANCER RESEARCH

Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies

(2010) Chryso Kanthou et al.   INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY

Identification of CKD-516: A Potent Tubulin Polymerization Inhibitor with Marked Antitumor Activity against Murine and Human Solid Tumors

(2010) Jaekwang Lee et al.   JOURNAL OF MEDICINAL CHEMISTRY

Enzymatic Depletion of Tumor Hyaluronan Induces Antitumor Responses in Preclinical Animal Models

(2010) C. B. Thompson et al.   MOLECULAR CANCER THERAPEUTICS

Delivering nanomedicine to solid tumors

(2010) Rakesh K. Jain et al.   Nature Reviews Clinical Oncology

Microtubule-binding agents: a dynamic field of cancer therapeutics

(2010) Charles Dumontet et al.   NATURE REVIEWS DRUG DISCOVERY

Blood-Brain Barrier Disruption with Focused Ultrasound Enhances Delivery of Chemotherapeutic Drugs for Glioblastoma Treatment

(2010) Hao-Li Liu et al.   RADIOLOGY

Impact of Nanotechnology on Drug Delivery

(2009) Omid C. Farokhzad et al.   ACS Nano

Combretastatin-like chalcones as inhibitors of microtubule polymerization. Part 1: Synthesis and biological evaluation of antivascular activity

(2009) Sylvie Ducki et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Selective Inhibition of Matrix Metalloproteinase-14 Blocks Tumor Growth, Invasion, and Angiogenesis

(2009) Laetitia Devy et al.   CANCER RESEARCH

Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models

(2009) L. G. Daenen et al.   MOLECULAR CANCER THERAPEUTICS

Slits and Roundabouts in cancer, tumour angiogenesis and endothelial cell migration

(2008) John A. Legg et al.   ANGIOGENESIS

Regulation of Endothelial Junctional Permeability

(2008) Emily Vandenbroucke et al.   Annals of the New York Academy of Sciences

Image-guided and passively tumour-targeted polymeric nanomedicines for radiochemotherapy

(2008) T Lammers et al.   BRITISH JOURNAL OF CANCER

Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors

(2008) Patricia M. LoRusso et al.   INVESTIGATIONAL NEW DRUGS

Macrophage activation and polarization

(2007) Fernando Oneissi Martinez   Frontiers in Bioscience-Landmark